102) r tissue carnitine or used carnitine as a treatment. |
103) work in the aftermath of prostate cancer treatment. |
104) rstanding of brain metastasis biology and treatment. |
105) = 3) compared with those of the control treatment. |
106) and "discuss the pros and cons" (83%) of treatment. |
107) hcare professionals (HCPs) to deliver the treatment. |
108) an efficient adsorbent in the wastewater treatment. |
109) r the endocytotic pathway within 4 h post treatment. |
110) regarding Lyme disease (LD) diagnosis and treatment. |
111) ith epilepsy beyond diagnosis and medical treatment. |
112) ication of ERPs in aphasia assessment and treatment. |
113) invasive alternative approach to tinnitus treatment. |
114) mit the utility of BCG for bladder cancer treatment. |
115) ciency of CD4+T cells following high salt treatment. |
116) t baseline and after 4 weeks of inpatient treatment. |
117) issues that can help inform diagnosis and treatment. |
118) no clinical practice guidelines to inform treatment. |
119) DU" may include being on anti-retroviral treatment and urban residency with drivers |
120) ew studies explicitly distinguished acute treatment and COT. |
121) ettings.METHODS: Key terms related to TB, treatment and adherence were used to searc |
122) uses on symptom management, discussion of treatment and care decisions, network orga |
123) But most researches will need in terms of treatment and disease control. |
124) hen at least yearly to ensure adequacy of treatment and encourage compliance. |
125) ust data may allow for improvement in the treatment and management of CVD in Indo-Ca |
126) This search yielded data that included treatment and management of myocardial inf |
127) s in order to personalize pharmacological treatment and offer cancer patients a bett |
128) uded to analyze nursing interventions for treatment and prevention. |
129) lar targets for new approaches to myeloma treatment and prevention. |
130) autoantibodies for 6 months after initial treatment and restored tolerance induction |
131) used as a novel approach to monitor drug treatment and sensitivity of primary BCP-A |
132) linical specimens and further augment the treatment and surveillance of coccidioidom |
133) edicinal materials (TMM) as endometriosis treatment and to explore its clinical appl |
134) ction and behavior following polypharmacy treatment and whether they are paralleled |
|